Immune Pharmaceuticals (IMNP) & Its Competitors Financial Analysis
Immune Pharmaceuticals (NASDAQ: IMNP) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Immune Pharmaceuticals to related businesses based on the strength of its institutional ownership, earnings, profitability, risk, valuation, analyst recommendations and dividends.
Insider & Institutional Ownership
1.6% of Immune Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.7% of Immune Pharmaceuticals shares are owned by insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current recommendations for Immune Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Immune Pharmaceuticals Competitors||881||3826||6812||181||2.54|
As a group, “Pharmaceuticals” companies have a potential upside of 18.97%. Given Immune Pharmaceuticals’ peers higher probable upside, analysts clearly believe Immune Pharmaceuticals has less favorable growth aspects than its peers.
Volatility and Risk
Immune Pharmaceuticals has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals’ peers have a beta of 34.63, indicating that their average stock price is 3,363% more volatile than the S&P 500.
This table compares Immune Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Immune Pharmaceuticals Competitors||-2,435.82%||-69.61%||-7.41%|
Earnings and Valuation
This table compares Immune Pharmaceuticals and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immune Pharmaceuticals||N/A||-$32.66 million||-0.24|
|Immune Pharmaceuticals Competitors||$8.17 billion||$1.09 billion||151.85|
Immune Pharmaceuticals’ peers have higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Immune Pharmaceuticals peers beat Immune Pharmaceuticals on 8 of the 9 factors compared.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.